VYBIO
Vybio focuses on the research and development of new drugs for oncology and hepatitis B. The core members of the team have 30 years of experience in tumor and hepatitis B drug research and development, and come from well-known pharmaceutical companies such as WuXi AppTec, Pfizer, BMS, etc., using a specific tumor microenvironment to independently innovate prodrug design and screening, and developed a series of global drugs. Preclinical research on precisely targeted small molecule anticancer prodrug compounds protected by intellectual property rights is being carried out in an orderly manner.
VYBIO
Industry:
Biotechnology Medical Oncology Pharmaceutical Therapeutics
Founded:
2018-01-01
Status:
Active
Email Addresses:
[email protected]
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
ARTyx
ARTyx helps in developing an avant-garde RNA therapeutic platform for cancer treatment With a preliminary focus on breast cancer.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Boston Biomedical
Boston Biomedical focuses on the research and development of novel therapeutics to treat cancer.
Longevity Biotech
Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.
Lukas Biomedical
Lukas Biomedical engages in the research and development of immunotherapy for cancer treatment.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
More informations about "Vybio"
Vybio - Crunchbase Company Profile & Funding
Vybio focuses on the research and development of new drugs for oncology and hepatitis B. The core members of the team have 30 years of experience in …See details»
Vybio - Crunchbase
Vybio focuses on the research and development of new drugs for oncology and hepatitis B.See details»
Vybion, Inc - BIO International Convention | BIO
Jun 6, 2023 · Vybion is a virtual gene therapy company with Orphan Designation from the FDA for a Huntington's Disease therapy. We have pioneered the vectorized antibody space and …See details»
Vybion - Crunchbase Company Profile & Funding
Vybion is a development stage company with platform technology for the development of a new drug class called Intrabodies. Their lead candidate for Huntington's and Azheimer's diseases …See details»
VYBION : Antibody Innovations
Feb 20, 2017 · Vybion is the leading developer of Intrabodies for neurodegenerative diseases, leveraging the safety and effectiveness of antibody technologies to address unmet medical …See details»
VYBION : Antibody Innovations
IND enabling studies for INT41 Gene Therapy for Huntington’s disease are in place following a preIND meeting with the FDA in in February 2022 in response to the briefing book prepared by …See details»
TFX05-01 in Advanced Solid Tumor - Clinical Trials …
Jun 10, 2022 · This is an open-label, non-randomized, multicenter, Phase Ⅰ/Ⅱa study to evaluate the safety, tolerability, pharmacokinetics and efficacy of TFX05-01 in patients with …See details»
Douglas Fang - VyBio Ltd. Co., | 领英 - 领英 (中国)
Role of Microphthalmia transcription factor (MITF) in regulation of melanocyte differentiation marker TRP-1. 工作经历: VyBio Ltd. Co., · 地点: 浦东新区 · 500 多位领英好友。 在领英 (一个 …See details»
Study of TFX06 in Women With Advanced Breast Cancer.
Jun 3, 2023 · Study of TFX06 in Women With Advanced Breast Cancer. Phase I/II Clinical Study to Evaluate the Safety, Tolerance, Efficacy and Pharmacokinetics of TFX06 Tablet in ER …See details»
Discovery and preclinical profile of YK-2168, a differentiated ...
Nov 1, 2024 · Electronic address: [email protected]. Emerging clinical evidence indicates that selective CDK9 inhibition may provide clinical benefits in the management of certain …See details»
Abstract - American Association for Cancer Research
May 2, 2024 · Aims: TFX06 is an investigational oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) (Wu J, et al., 2023 AACR annual meeting).See details»
Generation of a model colon cancer stem cell system …
Dec 1, 2007 · 2574 Background: PTC596 is an oral investigational new drug that reduces levels of BMI1, a protein required for CSC survival. PTC596 reduced the number of CSCs in …See details»
Biotechnology Innovation Organization - Wikipedia
The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry.See details»
Biotechnology Innovation Organization | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services.See details»
Biobased Economy Members – BIO
BIO is the only global organization that brings together biotech innovators to develop sustainable sources of food, feed, energy, biobased products, renewable chemicals, improved …See details»
Vybio - Tech Stack, Apps, Patents & Trademarks
Vybio focuses on the research and development of new drugs for oncology and hepatitis B.See details»
Transplant Diagnostics | Molecular Biology | Immunology
We are your leading supply partner for life sciences research and diagnostics including transplant diagnostics, molecular and cell biology and immunology.See details»
Ontario Bioscience Innovation Organization - Furthering the …
Founded in 2009, OBIO® is a not-for-profit, membership-based organization engaged in strategy, programming, policy development and advocacy to address the needs of the next generation …See details»
YGOrganization | Yu-Gi-Oh! news that ends misinformation
1 day ago · YGOrganization is the world’s most reliable information source for all Yu-Gi-Oh! news and content.See details»
Mingyu Pharmaceutical - Crunchbase
Vybio focuses on the research and development of new drugs for oncology and hepatitis B.See details»